{"id":"https://openalex.org/W7144812475","doi":null,"title":"Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance","display_name":"Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance","publication_year":2024,"publication_date":"2024-06-21","ids":{"openalex":"https://openalex.org/W7144812475"},"language":"en","primary_location":{"id":"pmh:oai:irdb.nii.ac.jp:00906:0006779923","doi":null,"is_oa":true,"landing_page_url":"https://tokushima-u.repo.nii.ac.jp/records/2007994","pdf_url":null,"source":{"id":"https://openalex.org/S7407056385","display_name":"Institutional Repositories DataBase (IRDB)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I184597095","host_organization_name":"National Institute of Informatics","host_organization_lineage":["https://openalex.org/I184597095"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"doctoral thesis"},"volume":null,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://tokushima-u.repo.nii.ac.jp/records/2007994","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5040862498","display_name":"Naoki Okamoto","orcid":"https://orcid.org/0000-0003-2371-5060","observed_orcids":["https://orcid.org/0000-0003-2371-5060"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Okamoto, Naoki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091588945","display_name":"Kenta Yagi","orcid":"https://orcid.org/0000-0003-0869-5786","observed_orcids":["https://orcid.org/0000-0003-0869-5786"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yagi, Kenta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5099340276","display_name":"Sayaka Imawaka","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Imawaka, Sayaka","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000240734","display_name":"Mayu Takaoka","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Takaoka, Mayu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024213569","display_name":"Fuka Aizawa","orcid":"https://orcid.org/0009-0008-1842-9303","observed_orcids":["https://orcid.org/0009-0008-1842-9303"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aizawa, Fuka","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046175614","display_name":"Takahiro Niimura","orcid":"https://orcid.org/0000-0003-2033-4246","observed_orcids":["https://orcid.org/0000-0003-2033-4246"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Niimura, Takahiro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063555500","display_name":"Mitsuhiro Goda","orcid":"https://orcid.org/0000-0001-5345-1479","observed_orcids":["https://orcid.org/0000-0001-5345-1479"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Goda, Mitsuhiro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110971238","display_name":"K\u00f4ji Miyata","orcid":"https://orcid.org/0009-0000-3954-6420","observed_orcids":["https://orcid.org/0009-0000-3954-6420"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Miyata, Koji","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082930612","display_name":"Kei Kawada","orcid":"https://orcid.org/0000-0003-1397-6128","observed_orcids":["https://orcid.org/0000-0003-1397-6128"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kawada, Kei","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5122862668","display_name":"Yuki Izawa-Ishizawa","orcid":"https://orcid.org/0000-0002-8178-9028","observed_orcids":["https://orcid.org/0000-0002-8178-9028"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Izawa-Ishizawa, Yuki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003077248","display_name":"Satoshi Sakaguchi","orcid":"https://orcid.org/0000-0002-8916-636X","observed_orcids":["https://orcid.org/0000-0002-8916-636X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sakaguchi, Satoshi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5131658494","display_name":"Keisuke Ishizawa","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ishizawa, Keisuke","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"12","issue":"4","first_page":"e1214","last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/asciminib","display_name":"asciminib","score":1.0},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.9769999980926514},{"id":"https://openalex.org/keywords/bcr-abl1","display_name":"BCR-ABL1","score":0.9269999861717224},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9950000047683716},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.9620000123977661},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8899999856948853},{"id":"https://openalex.org/keywords/synergistic-effect","display_name":"synergistic effect","score":0.6949999928474426},{"id":"https://openalex.org/keywords/allosteric-inhibitors","display_name":"allosteric inhibitors","score":0.9440000057220459},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.7319999933242798},{"id":"https://openalex.org/keywords/espn","display_name":"ESPN","score":0.949999988079071},{"id":"https://openalex.org/keywords/noxa1","display_name":"NOXA1","score":0.9950000047683716},{"id":"https://openalex.org/keywords/k562-cells","display_name":"K562 cells","score":0.8069999814033508},{"id":"https://openalex.org/keywords/cross-resistance","display_name":"cross-resistance","score":0.8460000157356262}],"concepts":[{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.8593999743461609},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6909000277519226},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6643000245094299},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6359999775886536},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.5357999801635742},{"id":"https://openalex.org/C2776120743","wikidata":"https://www.wikidata.org/wiki/Q3271540","display_name":"Mechanism of action","level":3,"score":0.5011000037193298},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4424999952316284},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.421099990606308},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.38850000500679016},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.3837999999523163},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.3709999918937683},{"id":"https://openalex.org/C89611455","wikidata":"https://www.wikidata.org/wiki/Q6804646","display_name":"Mechanism (biology)","level":2,"score":0.3578000068664551},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.3495999872684479},{"id":"https://openalex.org/C86380466","wikidata":"https://www.wikidata.org/wiki/Q5308872","display_name":"Drug action","level":3,"score":0.3476000130176544},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3172000050544739},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.30329999327659607},{"id":"https://openalex.org/C3454156","wikidata":"https://www.wikidata.org/wiki/Q1144241","display_name":"Side effect (computer science)","level":2,"score":0.3028999865055084},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.30219998955726624},{"id":"https://openalex.org/C166342909","wikidata":"https://www.wikidata.org/wiki/Q845326","display_name":"Allosteric regulation","level":3,"score":0.2971000075340271},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.29280000925064087},{"id":"https://openalex.org/C121587506","wikidata":"https://www.wikidata.org/wiki/Q6888113","display_name":"Mode of action","level":2,"score":0.29100000858306885},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.29030001163482666},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.26899999380111694},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.2653000056743622},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.2621999979019165}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:irdb.nii.ac.jp:00906:0006779923","doi":null,"is_oa":true,"landing_page_url":"https://tokushima-u.repo.nii.ac.jp/records/2007994","pdf_url":null,"source":{"id":"https://openalex.org/S7407056385","display_name":"Institutional Repositories DataBase (IRDB)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I184597095","host_organization_name":"National Institute of Informatics","host_organization_lineage":["https://openalex.org/I184597095"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"doctoral thesis"}],"best_oa_location":{"id":"pmh:oai:irdb.nii.ac.jp:00906:0006779923","doi":null,"is_oa":true,"landing_page_url":"https://tokushima-u.repo.nii.ac.jp/records/2007994","pdf_url":null,"source":{"id":"https://openalex.org/S7407056385","display_name":"Institutional Repositories DataBase (IRDB)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I184597095","host_organization_name":"National Institute of Informatics","host_organization_lineage":["https://openalex.org/I184597095"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"doctoral thesis"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2949253837","https://openalex.org/W2749744065","https://openalex.org/W2970415046","https://openalex.org/W7166310486","https://openalex.org/W4414780237","https://openalex.org/W2118234995","https://openalex.org/W2994033075","https://openalex.org/W4319040575","https://openalex.org/W4409286948","https://openalex.org/W2889101610"],"abstract_inverted_index":{"In":[0],"the":[1,30,51,70,76,87,94,105,147,161,170],"treatment":[2,17],"of":[3,75,78,96,149,151,164,172,191,194],"chronic":[4],"myeloid":[5],"leukemia":[6],"(CML),":[7],"resistance":[8,116],"to":[9,15,22,29,47,114,209],"BCR-ABL":[10,53,58,157,166,201],"inhibitors":[11,59,158,167,202],"makes":[12],"it":[13],"difficult":[14],"continue":[16],"and":[18,56,73,80,98,108,119,129,142,168,203],"is":[19,45,196],"directly":[20],"related":[21,113],"life":[23],"expectancy.":[24],"Therefore,":[25,67],"asciminib":[26,55,79,99,130,204],"was":[27,125],"introduced":[28],"market":[31],"as":[32,63,146,215,217],"a":[33],"useful":[34,46],"drug":[35,38,49,115],"for":[36],"overcoming":[37],"resistance.":[39,137,173],"While":[40],"combining":[41],"molecular":[42],"targeted":[43],"drugs":[44],"avoid":[48],"resistance,":[50],"new":[52],"inhibitor":[54],"conventional":[57,165],"should":[60],"be":[61,177,210],"used":[62],"monotherapy":[64],"in":[65,154],"principle.":[66],"we":[68],"investigated":[69],"synergistic":[71,123],"effect":[72,124],"mechanism":[74,193],"combination":[77,155],"imatinib.":[81],"We":[82],"generated":[83],"imatinib-resistant":[84],"cells":[85],"using":[86,104,117],"human":[88],"CML":[89],"cell":[90,102],"line":[91],"K562,":[92],"examined":[93],"effects":[95],"imatinib":[97,128,136],"exposure":[100],"on":[101],"survival":[103],"WST-8":[106],"assay,":[107],"comprehensively":[109],"analyzed":[110],"genetic":[111],"variation":[112],"RNA-seq":[118],"real-time":[120],"PCR.":[121],"A":[122],"observed":[126],"when":[127],"were":[131,144],"combined":[132],"with":[133,156],"or":[134],"without":[135],"Three":[138],"genes,":[139],"GRRP1,":[140],"ESPN,":[141],"NOXA1,":[143],"extracted":[145],"sites":[148],"action":[150,195],"asciminib.":[152],"Asciminib":[153],"may":[159,176,205],"improve":[160],"therapeutic":[162],"efficacy":[163],"prevent":[169],"development":[171],"Its":[174],"dosage":[175],"effective":[178],"even":[179],"at":[180],"minimal":[181],"doses":[182],"that":[183],"do":[184],"not":[185],"cause":[186],"side":[187],"effects.":[188],"Further":[189],"verification":[190],"this":[192],"needed.":[197],"Additionally,":[198],"cross-resistance":[199],"between":[200],"occur,":[206],"which":[207],"needs":[208],"clarified":[211],"through":[212],"further":[213],"validation":[214],"soon":[216],"possible.":[218]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-04-01T00:00:00"}